RecruitingPhase 2NCT07395687

A Research Study on How Well Different Doses of the Medicine UBT251 Help People Living With Overweight or Obesity

A Study Investigating Safety, Tolerability and Efficacy of UBT251 in Participants Living With Overweight or Obesity


Sponsor

Novo Nordisk A/S

Enrollment

333 participants

Start Date

Feb 2, 2026

Study Type

INTERVENTIONAL

Conditions

Summary

The purpose of this clinical study is to find out if UBT251 is safe and effective for treating people who are living with overweight or obesity. Participants will get either UBT251 (the treatment being tested) or Placebo (a treatment that has no active medicine in it), which treatment participants get is decided by chance.


Eligibility

Min Age: 18 YearsMax Age: 65 Years

Plain Language Summary

Simplified for easier understanding

This clinical trial is studying a drug called Placebo and a drug called UBT251 for people with obesity and overweight. The study is currently recruiting participants at 3 locations. People eligible for this study include aged 18 Years to 65 Years.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

DRUGUBT251

UBT251 injection will be administered subcutaneously in a lifted fold of the abdominal skin.

DRUGPlacebo

Placebo matched to UBT251 injection will be administered subcutaneously in a lifted fold of the abdominal skin.


Locations(3)

Altasciences Clinical LA, Inc.

Cypress, California, United States

Altasciences Clinical Kansas, Inc.

Overland Park, Kansas, United States

Altasciences Clinical Company, Inc

Montreal, Quebec, Canada

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT07395687


Related Trials